105
Participants
Start Date
November 2, 2021
Primary Completion Date
January 13, 2025
Study Completion Date
January 27, 2025
CPL500036 - low dose
CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
CPL500036 - high dose
CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
Placebo
Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
"Communal Enterprise Hospital of Zhytomyr City Council", Zhytomyr
Cherkasy Regional Hospital of the Cherkasy Regional Council, Cherkasy
"Medical Center of the Limited Liability Company Salyutem Medical Center", Vinnytsy
Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of the Poltava Regional Council, Poltava
Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Department of Neurology and Borderline Conditions;, Dnipro
Institute of Neurology, Psychiatry and Narcology of the Academy of Medical Sciences of Ukraine, Department of Vascular Pathology of the Brain and Rehabilitation, Kharkiv
"INET-09 LLC (Medical Center)", Zaporizhzhia
"Educational and Scientific Medical Center University Clinic of Zaporizhzhia State Medical University", Zaporizhzhia
"Treatment and Diagnostic Centre Neuro Global of the Limited Liability Company Neuro Global, Treatment and Prevention Sub-division", Ivano-Frankivsk
"Municipal non-profit enterprise of Lviv regional council Lviv regional clinical hospital, Neurological Department", Lviv
"Limited Liability Company, Medical Center DIAMED", Uzhhorod
Mazowiecki Szpital Bródnowski, Warsaw
Instytut Zdrowia dr Boczarska-Jedynak Sp. Z o.o., Sp. K.,, Oświęcim
"Medical center Dobrobut-Polyclinic Medical diagnostic center Dobrobut", Kyiv
"Medical Center of the Limited Liability Company Medical Center Consilium Medical", Kyiv
"D.F. Chebotaryov Institute of Gerontology of the National Academy of Medical Sciences of Ukraine", Kyiv
Lead Sponsor
National Center for Research and Development, Poland
OTHER
Celon Pharma SA
INDUSTRY